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Pharmacogenetics	 is	 essentially	 the	 study	 of	 genetic	 variation	 that	 influences	 an	
individual’s	response	to	drugs,	with	the	aim	of	guiding	prescription	practices	to	improve	
healthcare	quality	and	outcomes	(1).	The	term	pharmacogenetics	was	first	used	in	1959	





information	 (5).	The	FDA	currently	 requires	 genetic	 testing	 to	be	undertaken	prior	 to	











































at	 least	 one	 pharmacogenetic	 actionable	 gene	 variant	 (9,	 10).	 Demonstrating	 the	




the	 study	 conducted	 in	 the	United	Kingdom,	 three	pharmacogenes	 (CYP2D6,	 CYP2C19,	
SLCO1B1)	were	relevant	for	over	95%	of	prescribed	drugs	(12).	







2018	was	between	$18	million	 -	 $20	million	annually,	 thus	 the	occurrence	of	 adverse	










The	 activity	 of	 CYP450	 enzymes	 can	 vary	 greatly	 between	 individuals	 due	 to	 genetic	
variants.	 These	 can	 alter	 drug	 pharmacokinetics	 and	 often	 result	 in	 adverse	 drug	




1.2.1.  CYP2D6 
CYP2D6	encodes	the	liver	enzyme	Cytochrome	P450	2D6	(CYP2D6).	This	gene	is	located	








making	 up	 only	 2%	 of	 CYP	 enzyme	 liver	 content	 (27,	 28).	Metabolised	 drugs	 include	
metoprolol	 (antihypertensive	 -	 beta-blocker),	 codeine	 (analgesic	 -	 opioid),	 tamoxifen	
(antineoplastic	–	antioestrogen),	antidepressants	such	as	amitriptyline	and	paroxetine,	
and	many	others	(25,	29).		









true	 pseudogene	 (therefore	 denoted	 as	 CYP2D8P),	 having	 acquired	 many	 mutations	
which	render	it	unable	to	be	transcribed	or	translated.	CYP2D7	has	an	insertion	within	its	
first	exon	that	disrupts	the	reading	frame,	rendering	it	non-functional	(34,	35).		
1.2.2. Allelic Diversity of CYP2D6 
This	 gene	 is	 highly	 variable,	with	 gene	duplications,	 deletions,	 hybrids	 of	CYP2D6	and	
CYP2D7,	 or	 any	 number	 of	 variants	 reported	 to	 alter	 enzyme	 activity	 (36).	 The	
Pharmacogene	 Variation	 Consortium	 (PharmVar)	 seeks	 to	 record	 all	 variants	 present	
within	 CYP2D6.	 137	 allelic	 variants	 are	 currently	 reported	 on	 the	 PharmVar	website,	
ranging	from	CYP2D6*1	-	CYP2D6*145	(37).	Alleles	are	named	by	a	star	(*)	followed	by	a	
number	 to	 three	 decimal	 points	 (e.g.	 CYP2D6*1.046),	 in	 line	 with	 the	 format	
recommended	 by	 human	 gene	 nomenclature	 guidelines	 (37-39).	 Enzyme	 variants	 are	
noted	 similarly,	 but	 with	 a	 period	 as	 opposed	 to	 an	 asterisk	 (e.g.	 CYP2D6*10	 allele,	
CYP2D6.10	enzyme)	(39).		
Each	variant	 is	 categorised	 into	one	of	 four	metaboliser	phenotypes	 (Table	2)	–	ultra-
rapid	 metaboliser	 (UM),	 normal	 metaboliser	 (NM)	 (previously	 called	 extensive	
metaboliser),	 intermediate	metaboliser	(IM),	and	poor	metaboliser	(PM)	(40).	UMs	are	
characterised	 by	 one	 or	more	 gene	 duplications	without	 the	 presence	 of	 any	 inactive	
alleles	(>3	active	alleles);	NMs	(most	common	within	the	population,	ranging	from	72-




finally,	 PMs	 have	 two	 inactive	 alleles	 (41-43).	 Due	 to	 inconsistencies	 in	 assigning	
individuals	to	metaboliser	phenotypes,	Gaedigk	et	al.	proposed	an	activity	score	be	used	

















PM	or	UM	phenotype	are	at	 risk	of	drug	 toxicity,	 reduced	efficacy,	and	a	host	of	other	
adverse	drug	reactions	(46-49).		
Early	 pharmacogenetic	 studies	 stated	 ethnicity	 was	 non-specific	 when	 it	 came	 to	
predicting	pharmacogenetically	relevant	variants	(53-56).		More	recent	studies,	however,	










it	 is	 found	 at	 a	 frequency	 of	 only	 0.6%	 (59).	CYP2D6*17	 is	most	 common	 in	 the	 Sub-
Saharan	African	population	with	a	frequency	of	20%,	as	opposed	to	0.01%	in	East	Asians	
and	0.39%	in	Europeans.	This	holds	true	for	some	alleles	in	minority	populations,	such	as	
CYP2D6*82	 with	 an	 allele	 frequency	 of	 approximately	 3.6%	 in	 Mexican	 Mestizos	
population	and	0.05%	in	East	Asians,	with	no	reported	frequency	for	any	other	ethnicities	
(58).	
1.2.3. Sequencing of CYP2D6 
Many	 of	 the	 initial	CYP2D6	 (and	 related	 pseudogenes)	 discoveries	were	made	 via	 the	
technique	of	molecular	cloning	and	Sanger	sequencing.	All	variant	alleles	must	currently	
still	 undergo	Sanger	 sequencing	 for	 confirmation,	 as	 requested	by	PharmVar	 (33,	60).	
High-throughput	 second	 generation	 sequencing	 is	 often	 used	 and	 involves	 massively	
parallel	 sequencing	 a	 sample	 to	 generate	 a	 large	 number	 of	 reads	 (61).	 Targeted	
genotyping	 arrays	 are	 also	 frequently	 used	 as	 a	 cheap	 method	 to	 identify	 common	











investigate	 specific	 haplotypes	 is	 allele-specific	 long-range	 PCR;	 this	 method	 involves	
anchoring	PCR	primers	at	specific	variant	nucleotides	to	amplify	only	the	allele	of	interest	
(66).	CYP2D6	 is	 not	well	 suited	 to	 short-read	 technologies	 (<300bp	 reads)	 due	 to	 the	
presence	of	(and	high	homology	with)	the	pseudogenes	CYP2D7	and	CYP2D8P,	variants	
with	multiple	copy	numbers,	and	the	many	polymorphisms	which	exist	(25).	Analysis	of	
reproducible	 variant	 calling	 classified	 >20%	 of	 CYP2D6	 as	 unreliable,	 and	 the	 1000	
Genomes	Project	described	 the	gene	as	 ‘inaccessible’	 (67,	68).	 	 ‘Third	generation’	 long	
read	 sequencing	methods	 have	 since	 been	 developed	which	 overcome	 the	 difficulties	
faced	with	pseudogenes	and	copy	number	variations.		
1.3.  Nanopore Sequencing 
Nanopore	sequencing	was	first	imagined	in	the	1980s,	but	it	wasn’t	until	2005	that	Oxford	























(average	 single	molecule	 read	 of	 >10kb),	 high	 throughput	 and	 read	 depth,	 and	 short	














hours	 (81,	83).	 	Flow	cells	have	over	2000	nanopores,	whereas	a	 flongle	has	only	126	
nanopores,	leading	to	a	lower	throughput	and	longer	sequencing	run	time	(81).		






similar	genes)	 is	 the	difficulty	 the	nanopore	has	 in	discerning	homopolymeric	regions,	
leading	to	a	drop	in	read	depth	that	is	subsequently	miscalled	as	a	deletion	(84).		
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As	mentioned	 previously,	CYP2D6	 is	 often	 interrogated	 by	 targeted	 PCR,	 Sanger	 DNA	
sequencing,	 or	 array	 technology	 -	 these	 all	 provide	 genotypes	 but	 cannot	 readily	
discriminate	haplotypes.	A	large	advantage	to	using	nanopore	sequencing	is	the	ability	to	
analyse	 the	 entire	 gene,	 including	 novel	 variants	 and	 star	 alleles	 otherwise	missed	 in	
targeted	approaches.	Because	of	the	single	molecule	reads,	long	haplotypes	can	also	be	
discerned	 in	 a	direct	manner.	This	 is	 especially	beneficial	when	 looking	at	 individuals	
from	a	minority	population	who	may	carry	unknown	variants.		
1.4. Research in Minority Populations 
The	vast	majority	of	genomic	research	is	currently	carried	out	in	European	populations,	




Largely	 due	 to	 an	 increasing	 number	 of	 studies	 performed	 in	 Asia,	 the	 proportion	 of	
European	 studies	 is	 decreasing.	A	 five-fold	 increase	 in	non-European	 studies	between	
2009	and	2016	has	occurred,	but	78%	of	these	are	attributed	to	studies	in	East	Asia,	South	
Asia,	and	South-East	Asia	(primarily	Japan,	China,	Korea	and	India)	(87).	As	of	2016,	the	




Europeans,	 unexpected	 outcomes	 are	 likely	 to	 arise.	 Allele	 frequencies	 and	 linkage	
disequilibrium	can	differ	between	populations,	especially	those	which	are	highly	diverged	
(88).	 For	 example,	 a	 European	 study	 of	 prostate	 cancer	 risk	 alleles	was	 replicated	 in	




Minority	populations	need	 to	be	 included	 in	research.	Some	genetic	variants	exist	at	a	
higher	 frequency	 in	 these	 populations	 than	 within	 European	 populations,	 allowing	
associations	to	be	made	that	otherwise	would	be	missed.	An	example	is	a	CREBRF	gene	
variant	 (rs373863828)	which	 helps	 protect	 against	 gestational	 diabetes	mellitus.	 This	
variant	has	an	allele	frequency	of	10-27%	in	Māori	and	Pacific	Islanders,	compared	with	
just	0.004%	in	Europeans	(90).	
1.5. Research within Oceania 
Oceania	is	made	up	of	many	islands	located	within	the	Pacific	Ocean	and	divided	into	three	
regions	 –	 Melanesia	 (e.g.	 Papua	 New	 Guinea,	 Vanuatu,	 Fiji),	 Micronesia	 (e.g.	 Guam,	
Kiribati,	Marshall	Islands),	and	Polynesia	(e.g.	Hawaii,	Samoa,	Tonga,	Cook	Islands,	New	
Zealand)	 (91).	 	 Genetic	 research	 involving	 the	 indigenous	 populations	 of	 Oceania	 is	
severely	 lacking.	 Even	 articles	 published	 to	 highlight	 the	 importance	 of	 minority	
population	 inclusion	 in	 pharmacogenetics	 sometimes	 omit	 Oceania,	 instead	 focussing	
only	on	the	five	main	continents	-	Africa,	East	Asia,	South	Asia,	Europe,	and	the	Americas	
(92).	Those	that	do	include	Oceania	or	focus	specifically	on	Oceania	tend	to	only	look	at	
Papuan	 and	 Melanesian	 individuals.	 However	 populations	 within	 Oceania	 are	 very	












however	 it	 still	 led	 to	 the	media	making	 a	wide	 array	 of	 unsubstantiated	 claims	 that	
almost	certainly	damaged	Māori	trust	in	science	and	genomic	research	(97).	It	is	therefore	
important	to	ensure	any	and	all	research	involving	minority	populations	is	carried	out	
appropriately,	 with	 proper	 consultation,	 respect	 and	 cultural	 sensitivity.	 Cultural	
frameworks	 to	 work	 within	 often	 already	 exist,	 such	 as	 Te	 Mata	 Ira	 and	 Vision	
Mātauranga	for	Māori,	and	the	Pacific	Health	Research	Guidelines	for	Pasifika	(98-100).		






















debates	exist	 around	who	migrated	 to	 these	 islands	of	 remote	Oceania	 -	 groups	 living	
within	Near	Oceania,	or	a	new	group	of	individuals	who	swept	through	the	region,	or	a	
mix	of	both,	with	some	arguing	that	a	second	migration	replaced	the	founding	population	
on	 these	 islands	 (94,	 95,	 109,	 110).	 Genetically,	 Pacific	 Island	 populations	 are	 largely	
shown	to	have	their	origins	within	East	Asia,	with	little	to	no	admixture	with	the	Near	
Oceania	 populations,	 though	 this	 is	 still	 debated	 (111).	 If	 there	 has	 been	 little	 to	 no	
admixture	with	the	Near	Oceania	populations,	then	the	Oceania	studies	carried	out	as	part	
of	 worldwide	 research	 (e.g.	 1000	 genomes	 project)	 will	 not	 correctly	 represent	
Oceania/Pacific	Island	populations	and	many	assumptions	made	are	unlikely	to	hold	true.	
As	explained	above,	 these	studies	 tend	to	only	 incorporate	 individuals	 from	Melanesia	
and	 Papua	 New	 Guinea.	 Inferences	 made	 from	 East	 Asian	 populations	 will	 also	 be	
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services	 for	 treatment	 and	 prevention	 (115).	 Māori	 also	 experience	 higher	 levels	 of	
adverse	events	in	hospital,	some	of	which	could	be	pharmacogenetically	relevant	(115,	















Pasifika	 individuals	 are	 often	 picked	 up	 when	 CVD	 is	 at	 an	 advanced	 stage,	 so	 it	 is	
important	to	know	whether	their	prescribed	medication	course	is	optimal	(117).	Reduced	
or	 no	 response	 to	 cardiovascular	 disease	 medicine	 such	 as	 metoprolol	 could	 be	 a	
contributing	factor	for	Māori	and	Pasifika	populations	experiencing	a	high	CVD	mortality	
rate.		














































2.2. DNA Quality Check and Quantification 
2.2.1. Tape Station 
To	check	for	DNA	fragmentation,	selected	samples	were	prepared	according	to	Agilent	
Genomic	 DNA	 ScreenTape	 Assay	 Quick	 Guide	 for	 4200	 TapeStation	 System	 (Agilent	
Technologies,	Inc.,	Waldbronn,	Germany).	After	allowing	the	Genomic	DNA	Reagents	to	
reach	 room	 temperature,	 the	 Genomic	 DNA	 ScreenTape	 device	 was	 loaded	 into	 the	


















2.3.1. First round PCR 
CYP2D6	was	amplified	as	a	6.6kb	product,	covering	the	whole	gene	as	well	as	upstream	
and	downstream	non-coding	 regions.	 This	was	performed	 according	 to	Gaedigk	et	 al.,	
2007,	and	Liau	et	al.,	2019	(84,	126).		
Duplication	 (Dup)	 and	deletion	 (Del)	 primers	were	 used	 to	 identify	 the	 presence	 of	 a	
CYP2D6	duplication	or	deletion	via	amplification	of	a	3.5kb	fragment	(Figure	5).		
Protocol	modifications	made	 include	 combining	 the	 tailed	 and	duplication	 or	 deletion	
primer	within	 the	same	reaction,	as	opposed	 to	 separate	 reactions.	The	 following	was	
used	in	a	10µL	reaction:	1x	Kapa	LongRange	Buffer,	0.3mM	Kapa	dNTPs,	1.75mM	MgCl2,	
0.4µM	‘tailed’	forward	and	0.4µM	‘tailed’	reverse	primer,	0.3µM	duplication	or	deletion	
forward	 and	 reverse	 primer,	 50-100ng	 DNA,	 1M	 betaine,	 and	 0.25	 units	 of	 Kapa	
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LongRange	Taq	Polymerase,	with	remaining	volume	made	up	with	ultra-pure	H2O.	Kapa	
(Roche	 Diagnostics,	 Sigma-Aldrich,	 Indianapolis,	 Indiana,	 USA)	 included	 the	 Taq	
polymerase,	 buffer,	 MgCl2	 and	 dNTPs.	 The	 PCR	 cycle	 began	with	 94°C	 for	 3	minutes,	
followed	by	35	cycles	of	94°C	for	25	seconds,	68°C	for	10	seconds,	and	68°C	for	7	minutes,	
and	a	final	extension	step	of	72°C	for	7	minutes	then	25°C	for	5	minutes.	The	primary	PCR	
machine	used	was	 a	Mastercycler	ProS	Vapo	Protect	96	well	 6325	with	 a	 silver	block	
(Eppendorf,	Hamburg,	Germany).		
Due	to	supply	issues	caused	by	the	pandemic,	later	repeats	of	this	step	used	LongAMP	Hot	
Start	 Taq	 polymerase	 (New	 England	 Biolabs	 Inc.	 Ipswich,	 USA)	 instead	 of	 Kapa	
LongRange	Taq	Polymerase.	Subsequent	protocol	adjustments	used	5	units	of	LongAMP	
polymerase	and	omitted	MgCl2,	adding	additional	ultra-pure	H2O	instead.	
‘Tailed’	primers	amplify	 the	6.6kb	CYP2D6	 fragment	and	have	specific	 sequences	 from	

















2.3.2. ‘Nested’ Second-Round PCR 
If,	when	checked	on	a	gel	(Section	2.3.3),	a	faint	band	resulted	from	the	first	round	PCR,	a	
second	PCR	was	performed.	This	generated	a	higher	concentration	of	amplified	DNA	using	
the	 amplicon	 from	 the	 first	 PCR.	 In	 a	 50µL	 reaction,	 1µL	 of	 undiluted	 amplicon	 was	
amplified	with	1x	LongAMP	buffer,	0.3mM	Kapa	dNTPs,	0.7µM	‘tailed’	forward	primer	and	




































Oxford	 Nanopore	 Technologies	 PCR	 Barcoding	 Expansion	 1-96	 kit	 was	 used	 to	 add	
specific	 barcodes	 onto	 the	 CYP2D6	 product	 resulting	 from	 either	 the	 first	 round	 or	
‘nested’	second	round	PCR.	This	allowed	sample	pooling	 in	 later	steps.	 In	50µL,	0.5nM	
CYP2D6	 6.6kb	 tailed	 amplicon	 was	 amplified	 in	 the	 presence	 of	 1x	 LongAMP	 buffer,	
0.3mM	Kapa	dNTPs,	5	units	of	LongAMP	Hot	Start	Taq	DNA	polymerase,	0.2µM	barcode	
and	ultra-pure	H2O	to	make	up	the	 final	volume.	This	 followed	the	ONT	protocol	SQK-
LSK109,	 version	 PBAC96_9069_v109_revO_14Aug2019.	 The	 PCR	 cycle	 ran	 as	 follows:	
95°C	 for	3	minutes,	15	 cycles	of	95°C	 for	15	 seconds,	62°C	 for	15	 seconds,	65°C	 for	7	
minutes,	and	finally	65°C	for	7	minutes.		
2.3.5. Clean-up of Amplified Products 
Magnetic	beads	were	used	 to	purify	 the	PCR	products	both	prior	 to	and	 following	 the	
barcoding	 step.	 This	 removed	 DNA	 fragments	 shorter	 than	 3-4kb	 (to	 avoid	 off-target	
amplification)	and	other	impurities.		Following	the	protocol	of	Nagar	and	Schwessinger,	





of	 the	 DNA	 sample	 in	 a	 KingFisher	 96	 deep-well	 plate	 (ThermoFisher	 Scientific	 Inc,	
Waltham,	USA).	A	KingFisher	96	Deep-Well	Tip	Comb	was	 inserted	 into	 the	wells	 and	
agitated	gently	to	mix	the	beads	and	DNA	samples	for	a	period	of	5	minutes.	A	magnet	was	
then	placed	inside	these	tip	combs	for	approximately	5	minutes	or	until	the	supernatant	
was	 clear.	 Following	 this,	 the	 plastic	 tip	 comb	 and	 magnet	 were	 transferred	 to	 two	
KingFisher	deep-well	plates	each	containing	200µL	per	well	of	80%	ethanol	to	wash	the	
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2.4. Sequencing Library Preparation 
Prior	 to	 flow	 cell	 loading,	 each	DNA	 library	was	 prepared	 following	Oxford	Nanopore	
Technology	 protocol	 SQK-LSK109	 version	 PBAC96_9069_v109_revO_14Aug2019.	
Barcoded	amplicons	were	pooled	to	a	concentration	of	200	femtomoles	in	47µL	volume	
(using	 a	 speed	 evaporator	 (Eppendorf	 concentrator	 5301,	 Hamburg,	 Germany)	 if	 the	
initial	pooled	volume	exceeded	this)	before	undergoing	end-repair.	2µL	of	NEBNext	FFPE	
DNA	Repair	 enzyme	mix	and	3µL	of	Ultra	 II	End	Prep	enzyme	mix	plus	3.5µL	of	 each	
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respective	 buffer	 (all	 from	NEB,	 Ipswich,	 USA)	were	 combined	with	 the	 47µL	 pooled	
library	and	1µL	of	DNA	CS.	The	sample	was	mixed,	spun	down	and	then	incubated	at	20°C	














2.5. Nanopore Run 

































































2.7. Sanger Sequencing 







PCR	 cycling	 conditions	were	 as	 follows:	 94°C	 for	 2	minutes,	 15	 cycles	 of	 94°C	 for	 15	
seconds,	70°C	for	15	seconds,	72°C	for	1	minute;	followed	by	a	decrease	of	1°C	annealing	







































3.1. Optimising CYP2D6 Long PCR Protocol 
3.1.1. Taq Polymerase Testing 
At	the	outset	of	this	project,	supply	issues	caused	by	the	COVID-19	pandemic	were	known	
affecting	the	availability	of	Kapa	Long	Range	(LR)	Taq	polymerase,	an	enzyme	used	for	
the	development	of	 the	method	 (84).	Therefore,	 it	was	 important	 to	ensure	 the	 initial	
amplification	polymerase	chain	reaction	(PCR)	would	work	with	another	Taq	polymerase.	




Two	 positive	 controls	were	 included	 -	 UD262	which	was	 known	 to	 have	 one	 copy	 of	


























3.1.2. Combining PCR Reactions 
Due	 to	 the	aforementioned	supply	 issues,	an	effort	was	made	 to	conserve	reagents	by	
combining	two	PCRs	by	using	two	sets	of	primers	in	combination.	In	the	original	protocol,	
the	duplication/deletion	primers	were	used	alongside	primers	to	amplify	the	6.6kb	gene	







































3.2. Testing for Duplication or Deletion of CYP2D6 
3.2.1. GKD Cohort 
Once	 the	 assay	 was	 working	 as	 expected	 with	 LongAMP	 Taq	 polymerase	 and	 tailed	
primers,	cohort	samples	were	then	amplified.	Many	samples	within	the	GKD	cohort	failed		
































All	 samples	 from	 this	 cohort	were	 subjected	 to	 a	 nested	 PCR	 (Figure	 11)	 in	 order	 to	
increase	 the	 6.6kb	 amplicon	 DNA	 concentration	 to	 a	 level	 sufficient	 for	 nanopore	
sequencing.	Samples	which	continued	to	have	a	faint	or	absent	band	following	the	nested	
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intensity/brightness).	 Some	 lanes	 are	 quite	 smeared,	 potentially	 due	 to	 off	 target	
amplification	and/or	poor	DNA	quality.		
Out	 of	 the	 96	 samples	 in	 the	GKD	 cohort,	 two	 samples	 returned	 amplicons	 indicating	

















From	 the	96	 samples	within	 this	 cohort,	 47	produced	 satisfactory	bands	 after	 all	 PCR	
steps	and	were	therefore	taken	forward	for	nanopore	sequencing.		
3.2.2. Pasifika Heart Study Cohort 
The	Pasifika	Heart	Study	(PHS)	provided	96	samples	(numbered	hereafter	between	97	–	
192)	 in	 addition	 to	 the	 GKD	 cohort’s	 96.	 Ninety	 two	 of	 the	 PHS	 samples	 produced	
adequate	 bands	 at	 all	 stages	 of	 the	 analysis	 and	 therefore	 were	 taken	 forward	 for	




















Later	 repeats	 of	 the	 first-round	 PCR	 in	 different	 samples	 gave	 products	 of	 a	 lower	



















To	 test	 if	 the	 faint	 bands	 resulting	 from	 the	 first	 round	 PCR	 were	 due	 to	 a	 low	
concentration	 of	 DNA	 in	 the	 sample	 dilutions,	 all	 samples	 were	 measured	 via	
spectrophotometry	using	a	NanoDrop	8000.	This	was	then	repeated	and	compared	with	



















Sample	 Diluted	 Stock	260/280	 260/230	 ng/µL	 260/280	 260/230	 ng/µL	
121	 2.2	 0.8	 9.7	 2.1	 1.9	 83.4	
123	 2.0	 -1.2	 11.2	 2.0	 8.6	 75.2	
124	 2.0	 -7.3	 24.2	 2.0	 6.7	 90.5	
125	 2.0	 4.9	 34.8	 2.0	 -114.9	 66.7	
126	 1.9	 7.1	 47.3	 2.0	 -24.7	 54.1	
127	 1.9	 1.9	 47.1	 2.0	 1.7	 101.5	
128	 1.8	 0.9	 20.7	 2.0	 -51.7	 57.4	
129	 0.7	 -0.1	 1.3	 2.1	 -2.0	 32.7	
	
3.3. Checking DNA Quality 
Due	to	inconsistent	results	while	amplifying	DNA	from	some	of	the	samples,	raw	(pre-
PCR)	 DNA	 was	 checked	 for	 degradation	 on	 a	 TapeStation	 system	 (Agilent).	 For	 each	
















































3.4.1. Practice Flow Cell  
To	practice	running	through	the	protocol,	readily	available	laboratory	DNA	was	used	for	






1.0.8	 (137))	 reliably	 called	 the	 same	 star	 alleles	 as	 those	 identified	 through	 manual	













H1	 H2	 H1	 H2	
GAARD	22	 *2	 *4	 *2	 *4	
GAARD	23	 *1	 *4	 *1	 *4	
GAARD	24	 *1	 *4	 *1	 *4	
GAARD	25	 *1	 *2	 *1	 *2	
	
3.4.2. Nanopore Sequencing Flow Cell  
Once	the	practice	flow	cell	had	been	confidently	run	and	enough	samples	were	adequately	
amplified	after	all	PCR	steps,	two	flow	cells	were	successfully	loaded	for	two	separate	runs	
(performed	 at	 different	 times).	 Each	 sample	 was	 assigned	 a	 DNA	 barcode	 numbered	
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between	1	–	96.	CYP2D6	amplicons	from	a	total	of	142	samples	were	sequenced	during	





















































3.5.  Bioinformatics 







































































































































Star	allele	 Cohort	Allele	Frequency	 Activity	Score1	 Impact	
*1	 0.496	 1	 Normal	function	
*2	 0.138	 1	 Normal	function	
*4	 0.008	 0	 No	function	
*5	 0.021	 0	 No	Function	
*10	 0.167	 0.25	 Decreased	function	
*35	 0.008	 1	 Normal	function	
*41	 0.05	 0.5	 Decreased	function	
*71	 0.113	 ?	 Unknown	function	
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Figure	18	Allele	 frequencies	 of	 star	 alleles	 identified	within	 this	 study	 cohort	 compared	 to	 those	
reported	by	PharmGKB	for	European,	East	Asian,	and	Oceanian	populations.		
3.6.1. Statistical Test 






































Star	Allele	 P-value	 Chi-squared	Value	 95%	Confidence	Interval	
*1	 P	<	0.0001	 41.966	 16.63%	-	34.28%	
*2	 P	=	0.5692	 0.324	 -3.37%	-	9.01%	
*4	 P	=	0.6428	 0.215	 -0.37%	-	4.02%	
*5	 P	=	0.1559	 2.013	 -1.63%	-	4.28%	
*10	 P	<	0.0001	 35.135	 19.19%	-	32.56%	
*35	 P	=	0.0014	 10.172	 0.08%	-	4.46%	
*41	 P	=	0.0499	 3.845	 0.003%	-	8.18%	
 
3.6.2. CYP2D6 Metaboliser Status 
The	metaboliser	status	and	associated	frequency	was	inferred	from	the	genotype	of	each	
sample	 using	 the	 diplotype	 activity	 score	 defined	 by	 Caudle	 et	 al,	 2020	 (45).	 In	 this	
classification,	diplotypes	with	an	activity	score	of	0	are	classified	as	poor	metabolisers,	
0.25-1	 are	 intermediate	 metabolisers,	 1.25-2	 are	 normal	 metabolisers,	 and	 anything	







for	 European,	 East	 Asian,	 and	 Oceanian	 populations.	 Interestingly,	 the	 number	 of	





















Ultrarapid 0 0.031 0.014 0.206 
Normal 0.733 0.510 0.511 0.663 
Intermediate 0.050 0.389 0.391 0.101 
Poor 0 0.065 0.009 0.004 
Indeterminate 0.217 0 0.067 0.018 
	





























6419	(Intron	4)	 G>C	 	 Diplotype	is	*1/*1	











Using	 Ensembl’s	 VEP,	 Exonic	 variant	 6128	 was	 predicted	 as	 benign	 by	 PolyPhen	 but	





In	 addition	 to	 identifying	 novel	 variants,	 four	 potentially	 novel	 suballeles	 were	 also	
















































To	 our	 knowledge,	 this	 is	 the	 largest	 study	 to	 have	 been	 carried	 out	 on	 a	Māori	 and	
Pasifika	population	for	CYP2D6.	Of	the	nine	broad	ethnic	groups	defined	by	Huddart	et	al.,	
and	 reported	 by	 PharmGKB,	 Oceania	 is	 by	 far	 the	 least	 studied	 (58,	 144).	 	 We	 have	
successfully	 used	 nanopore	 sequencing	 to	 analyse	 the	whole	 CYP2D6	 gene	 (including	





into	metaboliser	 phenotypes.	We	did	 not	 find	 any	ultra-rapid	 or	 poor	metabolisers.	 A	
large	percentage	of	participants	(73%)	were	normal	metabolisers	and	5%	had	a	predicted	
activity	 score	within	 the	 range	of	 intermediate	metabolisers	 (45).	The	 remaining	22%	
were	unable	to	be	assigned	to	a	metaboliser	status	due	to	carrying	one	or	more	copies	of	
the	*71	allele.	To	date,	*71	has	not	been	extensively	studied	and	has	an	unknown	impact	
on	 the	CYP2D6	 enzyme.	 Six	 novel	 variants	 (including	missense	 and	 INDEL)	were	 also	
discovered,	one	of	which	is	exonic.	Four	known	variants	have	also	been	found	within	star	
alleles	 in	 which	 they	 have	 not	 been	 reported	 previously,	 potentially	 forming	 new	
suballeles.	
4.1. CYP2D6 Diversity in this Cohort 
The	allelic	frequencies	found	within	this	study	cohort	of	Māori	and	Pasifika	participants	
did	not	match	the	allelic	frequencies	previously	reported	by	PharmGKB	for	the	Oceanian	












five	 studies	 in	 the	 worldwide	 frequency	 table	 to	 report	 data	 on	 this	 allele.	 *71	 was	
detected	in	only	a	few	(five)	individuals,	much	less	than	our	cohort	frequency	of	0.113.		

















functional.	 If	an	 individual	was	 instead	*1/*71	or	*71/*71,	 they	would	be	classified	as	
*1/*1	and	assigned	as	a	normal	metaboliser.	If	this	allele	is	nonfunctional,	then	the	drug	
prescription	received	by	the	individual	would	not	be	accurate,	as	they	are	instead	a	poor	
metaboliser	 or	 intermediate	metaboliser.	 Therefore	 the	 individual	would	be	 at	 risk	 of	
adverse	drug	effects	and/or	nonresponse	to	the	medication.		
For	minority	populations,	 it	 is	 far	more	suitable	 to	use	a	 technology	such	as	nanopore	
sequencing	due	to	the	ability	to	interrogate	all	known	star	alleles	and	potentially	discover	














terminus.	Clearly,	 *71	 is	 a	 significant	 area	 for	 future	 research,	with	phenotyping	via	 a	
probe	 drug	 necessary	 to	 conclude	what	 effect	 the	 variants	 in	 this	 star	 allele	 have	 on	
	 67	
CYP2D6	 enzyme	 function.	 Assuming	 Zhou	 et	 al.,	 were	 correct,	 significantly	 more	
individuals	within	our	study	would	be	classed	as	intermediate	metabolisers,	including	a	
low	frequency	of	poor	metabolisers.	The	majority	of	our	samples	were	classified	based	on	
their	 diplotype	 activity	 score	 to	 be	 normal	 metabolisers	 (45).	 This	 means	 these	
individuals	 are	 likely	 to	 experience	 the	 desired	 therapeutic	 effects	 from	 drugs	
metabolised	by	CYP2D6,	such	as	metoprolol.		
Oceania	is	reported	to	have	an	ultrarapid	metaboliser	rate	of	20%,	however	no	ultrarapid	





more	 accurately	 portray	 haplotypes.	 More	 accurate	 allele	 frequencies	 for	 these	
populations	 may	 also	 be	 obtained	 if	 more	 specific	 categorisation	 was	 used,	 such	 as	
splitting	Oceania	up	further	into	Melanesia,	Micronesia,	and	Polynesia.			
4.2. Novel Variants and Suballeles 






amino	acid	 from	glutamic	acid,	an	acidic	amino	acid,	 to	 lysine,	a	basic	amino	acid.	 It	 is	












When	 these	 novel	 variants	 were	 entered	 into	 Ensembl’s	 Variant	 Effect	 Predictor,	 the	
variant	 at	 6128	 was	 predicted	 to	 be	 likely	 deleterious	 by	 SIFT	 and	 likely	 benign	 by	
PolyPhen.	SIFT	uses	sequence	homology	and	physico-chemical	similarities	between	the	
alternate	amino	acids,	with	a	score	below	0.005	giving	a	‘deleterious’	score,	and	anything	




haplotype	each	variant	exists	on,	 enabling	 straightforward	phasing	 (84).	 In	 this	 study,	
about	20%	of	samples	were	identified	during	analysis	as	having	incorrect	phasing	which	
led	 to	 some	 variants	 being	 incorrectly	 haplotyped.	 This	 could	 only	 be	 resolved	 by	
manually	inspecting	the	BAM	files	of	each	sample	on	IGV	and	visualising	each	problematic	
variant	as	being	split	~50/50	over	both	haplotypes.	While	 the	star	alleles	which	were	
assigned	 to	 these	 samples	 were	 assigned	 quite	 confidently	 with	 reference	 to	 the	









LR	 claims	 to	 have	 3-4x	 higher	 fidelity	 than	 Taq	 polymerase	 alongside	 an	 engineered	
polymerase	with	proofreading	ability	(157).	In	light	of	these	polymerase	differences,	it	is	
possible	 the	 incorrectly	 phased	 variants	 arose	 from	 LongAMP	 lacking	 proofreading	
ability.	

















































The	 second	 cohort,	 Pasifika	 Heart	 Study,	 had	 a	 much	 greater	 number	 of	 successfully	



















fourth	 time	 this	 flow	 cell	 had	 been	 used,	 and	 still	 10x	more	 available	 pores	 than	 the	
flongle.	The	flow	cell	also	generated	a	lower	number	of	reads	for	each	sample	than	seen	












using	 low-pass	whole	 genome	 sequencing	 increases	 the	difficulty	 of	 interrogating	 this	
region.	CYP2D6	has	been	interrogated	previously	using	whole	genome	sequencing	(high-
pass,	30x	read	depth),	but	extra	caution	needs	to	be	taken	when	performing	analysis	of	
the	 gene	 region,	 and	 specific	bioinformatic	 tools	 are	usually	 employed,	 such	as	Cyrius	
(167).		









of	 this	 allele	 is	 an	 important	 next	 step.	 This	 can	 be	 done	 with	 a	 probe	 drug	 such	 as	
dextromethorphan	or	via	use	of	hepatic	cell	lines	(168,	169).	Understanding	the	function	
of	this	allele	will	allow	an	activity	score	and	metaboliser	phenotype	to	be	assigned	to	all	
participants	 of	 this	 study	 and	 allow	 for	 a	 greater	 understanding	 of	 the	 CYP2D6	
metaboliser	statuses	existing	within	the	Māori	and	Pasifika	population.		
4.6. Conclusions 
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Ethnicity Details of Each Cohort 
Table	15	Ethnicity	and	Sex	Details	from	GKD	Cohort	
Ethnicity Breakdown Female Male Number of Samples 




0.5 NZ Māori 0.5 CI Māori 
 
1 1 
0.5 Samoan 0.5 Tongan 
 
1 1 





0.75 NZ Māori 0.25 Caucasian 3 2 5 
0.75 Samoan 1 
 
1 
0.875 NZ Māori 0.125 
Caucasian 




1.0 NZ Māori 11 6 17 




1.0 Tongan 3 3 6 







Primary Ethnicity Other Ethnicity 1 Other Ethnicity 2 Other Ethnicity 3 
Female 42 6 2 
 
Cook Island Māori 3 1 
  
Fijian 4 
   
NZ European 3 3 1 
 
NZ Māori 1 1 1 
 
Samoan 24 1 
  
Tongan 7 
   
     
Male 43 6 2 2 
Cook Island Māori 1 
   
Fijian 9 2 
 
1 
Samoan 23 4 2 1 
Tongan 10 
   
     
Grand Total 85 12 4 2 
Includes	all	sequenced	and	analysed	samples.	
‘Other	ethnicity’	refers	to	the	number	of	individuals	self-reporting	additional	ethnicities	alongside	
their	primary	ethnicity.		
	
